Former eGenesis CEO joins vTv as it tries to make a comeback; Eisai nabs Alzheimer’s commercial exec amid lecanemab push
While Rich Nelson is out as interim CEO of vTv Therapeutics, he will be continuing as the company’s EVP of corporate development as Paul Sekhri takes the mantle of president and CEO on Aug. 1.
In Nelson’s four short months as head of the North Carolina-based biotech, he saw G42 Healthcare, a UAE health tech company, invest in vTv and agree to collaborate on vTv’s Phase III study for a type I diabetes treatment. Prior to Nelson’s stepping in as CEO, Deepa Prasad had served as CEO, though she too was only there for a few months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.